Clinical Trial Search

Primary: Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy — 0; 0; 18; 13 Participants

Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants

Primary: Response Rate — 1; 2; 23; 3 Participants

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants

Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…

Primary: Response Rate — 0; 0; 1; 0 participants

Primary: Best Overall Response Rate — 2; 5; 17; 8 Participants

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants

Primary: Sentinel Lymph Node Positivity — 2 Participants

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: 1-year Local Control — NA; NA months

Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…

Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants

Primary: Duration of Local Control — 4.6 number of months to local failure

Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants

Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants

Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants

Primary: Number of Patients With Local Failure Following SABR Treatment of Early Glottic Larynx Cancers — 2 participants

Primary: Local Control Rate — 1; 5 Participants

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline

Primary: Xerostomia Questionnaire Scores — 57.3; 50.6; 55.0; 55.2 score on a scale 0-80 — p=0.0167

Primary: Xerostomia One Month After Completion of Treatment — 5; 7; 1; 6 Participants

Primary: Number of Participants Demonstrating the Safety and Tolerability of Long Term Erlotinib Treatment — 26; 22; 22; 6 participants